The cardiovascular benefits of SGLT2 inhibitors seen in randomised controlled trials are also evident in real world practice, according to an observational study that involved more than 200,000 Australian patients with type 2 diabetes. And results from the multinational study also suggest that the cardiovascular benefits apply in lower risk patients and not just those ...
Australian real world data confirm cardiovascular benefits of SGLT-2 inhibitors
By Michael Woodhead
24 Aug 2018